- Home
- CMRX vs SSBK Comparison
CMRX vs SSBK Comparison
Compare CMRX & SSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRX
- SSBK
- Stock Information
- Founded
- CMRX 2000
- SSBK 2007
- Country
- CMRX United States
- SSBK United States
- Employees
- CMRX 81
- SSBK N/A
- Industry
- CMRX Biotechnology: Pharmaceutical Preparations
- SSBK Commercial Banks
- Sector
- CMRX Health Care
- SSBK Finance
- Exchange
- CMRX Nasdaq
- SSBK Nasdaq
- Market Cap
- CMRX 797.3M
- SSBK N/A
- IPO Year
- CMRX 2013
- SSBK 2021
- Fundamental
- Price
- CMRX $8.50
- SSBK $35.97
- Analyst Decision
- CMRX Hold
- SSBK Buy
- Analyst Count
- CMRX 4
- SSBK 1
- Target Price
- CMRX $8.51
- SSBK $36.00
- AVG Volume (30 Days)
- CMRX 8.4M
- SSBK 26.3K
- Earning Date
- CMRX 03-21-2025
- SSBK 04-21-2025
- Dividend Yield
- CMRX N/A
- SSBK 1.01%
- EPS Growth
- CMRX N/A
- SSBK 3.77
- EPS
- CMRX N/A
- SSBK 3.67
- Revenue
- CMRX $212,000.00
- SSBK $94,140,000.00
- Revenue This Year
- CMRX $2,685.38
- SSBK $19.13
- Revenue Next Year
- CMRX $1,050.23
- SSBK $7.78
- P/E Ratio
- CMRX N/A
- SSBK $9.69
- Revenue Growth
- CMRX N/A
- SSBK 13.56
- 52 Week Low
- CMRX $0.75
- SSBK $22.13
- 52 Week High
- CMRX $8.53
- SSBK $39.16
- Technical
- Relative Strength Index (RSI)
- CMRX 83.05
- SSBK 73.48
- Support Level
- CMRX $8.41
- SSBK $32.06
- Resistance Level
- CMRX $8.52
- SSBK $36.30
- Average True Range (ATR)
- CMRX 0.02
- SSBK 0.81
- MACD
- CMRX -0.15
- SSBK 0.43
- Stochastic Oscillator
- CMRX 62.50
- SSBK 95.95
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.